Page 1280 - Williams Hematology ( PDFDrive )

1254 Part IX: Lymphocytes and Plasma Cells Chapter 81: Hematologic Manifestations of Acquired Immunodeficiency Syndrome 1255

34. Allen BJ, Raja C, Rizvi S, et al: Intralesional targeted alpha therapy for metastatic mela- 61. Hammer SM, Squires KE, Hughes MD, et al: A controlled trial of two nucleoside ana-
noma. Cancer Biol Ther 4:1318–1324, 2005. logues plus indinavir in persons with human immunodeficiency virus infection and
35. Allen TM, Altfeld M, Yu XG, et al: Selection, transmission, and reversion of an CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320
antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodefi- Study Team. N Engl J Med 337:725–733, 1997.
ciency virus type 1 infection. J Virol 78:7069–7078, 2004. 62. Walmsley S, Bernstein B, King M, et al: Lopinavir-ritonavir versus nelfinavir for the
36. Allen TM, Altfeld M, Geer SC, et al: Selective escape from CD8+ T-cell responses initial treatment of HIV infection. N Engl J Med 346:2039–2046, 2002.
represents a major driving force of human immunodeficiency virus type 1 (HIV-1) 63. Palella FJ Jr, Delaney KM, Moorman AC, et al: Declining morbidity and mortal-
sequence diversity and reveals constraints on HIV-1 evolution. J Virol 79:13239–13249, ity among patients with advanced human immunodeficiency virus infection. HIV
2005. Outpatient Study Investigators. N Engl J Med 338:853–860, 1998.
37. Deeks SG, Kitchen CM, Liu L, et al: Immune activation set point during early HIV 64. Kalayjian RC, Franceschini N, Gupta SK, et al: Suppression of HIV-1 replication by
infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood antiretroviral therapy improves renal function in persons with low CD4 cell counts and
104:942–947, 2004. chronic kidney disease. AIDS 22:481–487, 2008.
38. Deeks SG, Tracy R, Douek DC: Systemic effects of inflammation on health during 65. Brau N, Salvatore M, Rios-Bedoya CF, et al: Slower fibrosis progression in HIV/HCV-
chronic HIV infection. Immunity 39:633–645, 2013. coinfected patients with successful HIV suppression using antiretroviral therapy.
39. Douek DC, Roederer M, Koup RA: Emerging concepts in the immunopathogenesis of J Hepatol 44:47–55, 2006.
AIDS. Annu Rev Med 60:471–484, 2009. 66. Loko MA, Bani-Sadr F, Valantin MA, et al: Antiretroviral therapy and sustained virol-
40. Giorgi JV, Hultin LE, McKeating JA, et al: Shorter survival in advanced human immu- ogical response to HCV therapy are associated with slower liver fibrosis progression in
nodeficiency virus type 1 infection is more closely associated with T lymphocyte acti- HIV-HCV-coinfected patients: Study from the ANRS CO 13 HEPAVIH cohort. Antivir
vation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis Ther 17:1335–1343, 2012.
179:859–870, 1999. 67. Thorpe J, Saeed S, Moodie EE, et al: Antiretroviral treatment interruption leads to
41. Liu Z, Cumberland WG, Hultin LE, et al: Elevated CD38 antigen expression on CD8+ progression of liver fibrosis in HIV-hepatitis C virus co-infection. AIDS 25:967–975,
T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and 2011.
death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune 68. Limketkai BN, Mehta SH, Sutcliffe CG, et al: Relationship of liver disease stage and
activation markers, or combinations of HLA-DR and CD38 expression. J Acquir antiviral therapy with liver-related events and death in adults coinfected with HIV/
Immune Defic Syndr Hum Retrovirol 16:83–92, 1997. HCV. JAMA 308:370–378, 2012.
42. Brenchley JM, Price DA, Schacker TW, et al: Microbial translocation is a cause of sys- 69. Neuhaus J, Jacobs DR, Jr., Baker JV, et al: Markers of inflammation, coagulation, and
temic immune activation in chronic HIV infection. Nat Med 12:1365–1371, 2006. renal function are elevated in adults with HIV infection. J Infect Dis 201:1788–1795,
43. Zeng M, Smith AJ, Wietgrefe SW, et al: Cumulative mechanisms of lymphoid tissue 2010.
fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest 121:998–1008, 70. El-Sadr WM, Lundgren J, Neaton JD, et al: CD4+ count-guided interruption of antiret-
2011. roviral treatment. N Engl J Med 355:2283–2296, 2006.
44. Zeng M, Southern PJ, Reilly CS, et al: Lymphoid tissue damage in HIV-1 infection 71. Bhaskaran K, Mussini C, Antinori A, et al: Changes in the incidence and predictors of
depletes naive T cells and limits T cell reconstitution after antiretroviral therapy. PLoS human immunodeficiency virus-associated dementia in the era of highly active antiret-
Pathog 8:e1002437, 2012. roviral therapy. Ann Neurol 63:213–221, 2008.
45. Freiberg MS, Chang CC, Kuller LH, et al: HIV infection and the risk of acute myocar- 72. d’Arminio Monforte A, Cinque P, Mocroft A, et al: Changing incidence of central ner-
dial infarction. JAMA Intern Med 173:614–622, 2013. vous system diseases in the EuroSIDA cohort. Ann Neurol 55:320–328, 2004.
46. Weber R, Sabin CA, Friis-Moller N, et al: Liver-related deaths in persons infected with 73. Townsend CL, Cortina-Borja M, Peckham CS, et al: Low rates of mother-to-child trans-
the human immunodeficiency virus: The D:A:D study. Arch Intern Med 166:1632–1641, mission of HIV following effective pregnancy interventions in the United Kingdom and
2006. Ireland, 2000–2006. AIDS 22:973–981, 2008.
47. Balagopal A, Ray SC, De Oca RM, et al: Kupffer cells are depleted with HIV immu- 74. Tubiana R, Le Chenadec J, Rouzioux C, et al: Factors associated with mother-to-child
nodeficiency and partially recovered with antiretroviral immune reconstitution. AIDS transmission of HIV-1 despite a maternal viral load <500 copies/ml at delivery: A case-
23:2397–2404, 2009. control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis
48. Peters L, Neuhaus J, Mocroft A, et al: Hyaluronic acid levels predict increased risk of 50:585–596, 2010.
non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in 75. Coombs RW, Reichelderfer PS, Landay AL: Recent observations on HIV type-1 infec-
the SMART Study. Antivir Ther 16:667–675, 2011. tion in the genital tract of men and women. AIDS 17:455–480, 2003.
49. Duprez DA, Neuhaus J, Kuller LH, et al: Inflammation, coagulation and cardiovascular 76. Keiser O, Fellay J, Opravil M, et al: Adverse events to antiretrovirals in the Swiss
disease in HIV-infected individuals. PLoS One 7:e44454, 2012. HIV Cohort Study: Effect on mortality and treatment modification. Antivir Ther 12:
50. Shen YM, Frenkel EP: Thrombosis and a hypercoagulable state in HIV-infected 1157–1164, 2007.
patients. Clin Appl Thromb Hemost 10:277–280, 2004. 77. O’Brien ME, Clark RA, Besch CL, et al: Patterns and correlates of discontinuation of
51. Lijfering WM, Sprenger HG, Georg RR, et al: Relationship between progression to the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr
AIDS and thrombophilic abnormalities in HIV infection. Clin Chem 54:1226–1233, 34:407–414, 2003.
2008. 78. Fidler S, Porter K, Ewings F, et al: Short-course antiretroviral therapy in primary HIV
52. Fischl MA, Richman DD, Grieco MH, et al: The efficacy of azidothymidine (AZT) infection. N Engl J Med 368:207–217, 2013.
in the treatment of patients with AIDS and AIDS-related complex. A double-blind, 79. Grijsen ML, Steingrover R, Wit FW, et al: No treatment versus 24 or 60 weeks of antiret-
placebo-controlled trial. N Engl J Med 317:185–191, 1987. roviral treatment during primary HIV infection: The randomized Primo-SHM trial.
53. Fischl MA, Richman DD, Hansen N, et al: The safety and efficacy of zidovudine (AZT) PLoS Med 9:e1001196, 2012.
in the treatment of subjects with mildly symptomatic human immunodeficiency virus 80. Hogan CM, Degruttola V, Sun X, et al: The setpoint study (ACTG A5217): Effect of
type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-
Trials Group. Ann Intern Med 112:727–737, 1990. 1-infected individuals. J Infect Dis 205:87–96, 2012.
54. Lundgren JD, Phillips AN, Pedersen C, et al: Comparison of long-term prognosis of 81. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus
patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study type 1 seroconverters. Arch Intern Med 171:1560–1569, 2011.
Group. JAMA 271:1088–1092, 1994. 82. Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al: Long-term immunovirologic con-
55. Richman DD, Fischl MA, Grieco MH, et al: The toxicity of azidothymidine (AZT) trol following antiretroviral therapy interruption in patients treated at the time of pri-
in the treatment of patients with AIDS and AIDS-related complex. A double-blind, mary HIV-1 infection. AIDS 24:1598–1601, 2010.
placebo-controlled trial. N Engl J Med 317:192–197, 1987. 83. Le T, Wright EJ, Smith DM, et al: Enhanced CD4+ T-cell recovery with earlier HIV-1
56. Volberding PA, Lagakos SW, Grimes JM, et al: A comparison of immediate with antiretroviral therapy. N Engl J Med 368:218–230, 2013.
deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell 84. Strain MC, Little SJ, Daar ES, et al: Effect of treatment, during primary infection, on
counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 191:1410–1418,
333:401–407, 1995. 2005.
57. Volberding PA, Lagakos SW, Koch MA, et al: Zidovudine in asymptomatic human 85. Ananworanich J, Schuetz A, Vandergeeten C, et al: Impact of multi-targeted antiret-
immunodeficiency virus infection. A controlled trial in persons with fewer than 500 roviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV
CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National infection. PLoS One 7:e33948, 2012.
Institute of Allergy and Infectious Diseases. N Engl J Med 322:941–949, 1990. 86. Archin NM, Vaidya NK, Kuruc JD, et al: Immediate antiviral therapy appears to restrict
58. Montaner JS, Reiss P, Cooper D, et al: A randomized, double-blind trial comparing resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection.
combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The Proc Natl Acad Sci U S A 109:9523–9528, 2012.
INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 279:930–937, 87. Chun TW, Justement JS, Moir S, et al: Decay of the HIV reservoir in patients receiv-
1998. ing antiretroviral therapy for extended periods: Implications for eradication of virus.
59. Cameron DW, Japour AJ, Xu Y, et al: Ritonavir and saquinavir combination therapy for J Infect Dis 195:1762–1764, 2007.
the treatment of HIV infection. AIDS 13:213–224, 1999. 88. Saez-Cirion A, Bacchus C, Hocqueloux L, et al: Post-treatment HIV-1 controllers with
60. Gulick RM, Mellors JW, Havlir D, et al: 3-year suppression of HIV viremia with indina- a long-term virological remission after the interruption of early initiated antiretroviral
vir, zidovudine, and lamivudine. Ann Intern Med 133:35–39, 2000. therapy ANRS VISCONTI Study. PLoS Pathog 9:e1003211, 2013.

Kaushansky_chapter 81_p1239-1260.indd 1255 9/21/15 11:19 AM